Back to Journals » Cancer Management and Research » Volume 11

Common molecular markers between circulating tumor cells and blood exosomes in colorectal cancer: a systematic and analytical review

Authors Vafaei S, Fattahi F, Ebrahimi M, Janani L, Shariftabrizi A, Madjd Z

Received 17 June 2019

Accepted for publication 15 August 2019

Published 25 September 2019 Volume 2019:11 Pages 8669—8698

DOI https://doi.org/10.2147/CMAR.S219699

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Seema Singh


Somayeh Vafaei,1–3 Fahimeh Fattahi,1,2 Marzieh Ebrahimi,3 Leila Janani,4 Ahmad Shariftabrizi,5 Zahra Madjd1,6

1Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran; 2Student Research Committee, Iran University of Medical Sciences, Tehran, Iran; 3Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; 4Department of Biostatistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran; 5Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; 6Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran

Correspondence: Zahra Madjd
Oncopathology Research Center, Department of Molecular Medicine, Iran University of Medical Sciences (IUMS), Hemmat Street (Highway), Next to Milad Tower, Tehran 14496-14530, Iran
Tel +98 218 670 3212
Fax +98 218 862 2608
Email Zahra.madjd@yahoo.com
Marzieh Ebrahimi
Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 16635-148, Iran
Tel +98 2 356 2516
Email mebrahimi@royaninstitute.org

Abstract: Nearly half of patients with colorectal cancer (CRC), the third leading cause of cancer deaths worldwide, are diagnosed in the late stages of the disease. Appropriate treatment is not applied in a timely manner and nearly 90% of the patients who experience metastasis ultimately die. Timely detection of CRC can increase the five-year survival rate of patients. Existing histopathological and molecular classifications are insufficient for prediction of metastasis, which limits approaches to treatment. Detection of reliable cancer-related biomarkers can improve early diagnosis, prognosis, and treatment response prediction and recurrence risk. Circulating tumor cells (CTCs) and exosomes in peripheral blood can be used in a liquid biopsy to assess the status of a tumor. Exosomes are abundant and available in all fluids of the body, have a high half-life and are released by most cells. Tumor-derived exosomes are released from primary tumors or CTCs with selective cargo that represents the overall tumor. The current systematic review highlights new trends and approaches in the detection of CRC biomarkers to determine tumor signatures using CTC and exosomes. When these are combined, they could be used to guide molecular pathology and can revolutionize detection tools. Relevant observational studies published until July 24, 2019 which evaluated the expression of tumor markers in CTCs and exosomes were searched in PubMed, Scopus, Embase, and ISI Web of Science databases. The extracted biomarkers were analyzed using String and EnrichR tools.

Keywords: colorectal cancer, circulating tumor cell, CTC, exosomes, diagnosis, prognosis, biomarker, systematic review

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]